

## Return on Investment

Every pig represents an investment already made. By protecting this investment from negative performance caused by disease, continued economic return may be realized.

The following chart shows the net return on investment of vaccinating growing pigs, by calculating the economic benefits of increasing ADG and decreasing mortality.

### Example: Net Return on Vaccination Investment

		Average Daily Gain (ADG) Difference (in lbs.)						
		0.00	0.05	0.10	0.15	0.20	0.25	0.30
Mortality Reduction	0%	(\$1.00)	\$0.61	\$2.23	\$3.84	\$5.46	\$7.07	\$8.69
	1%	(\$0.35)	\$1.28	\$2.91	\$4.54	\$6.18	\$7.81	\$9.44
	2%	\$0.30	\$1.95	\$3.60	\$5.25	\$6.89	\$8.54	\$10.19
	3%	\$0.94	\$2.61	\$4.28	\$5.95	\$7.61	\$9.28	\$10.95
	4%	\$1.59	\$3.28	\$4.96	\$6.65	\$8.33	\$10.02	\$11.70
	5%	\$2.24	\$3.94	\$5.64	\$7.35	\$9.05	\$10.75	\$12.45
	6%	\$2.89	\$4.61	\$6.33	\$8.05	\$9.77	\$11.49	\$13.21

  = Calculated Net ROI when using Ingelvac PRRS vaccines

Average weight in = 45 lbs per pig  
Average Days-On-Feed = 130 days

Market Price = \$45 per 100 lb live  
Feed Cost = \$120 per ton of feed

Base ADG = 1.50 lb gain per head per day  
Base FCR = 3.00 lb feed per lb of gain  
Base Mortality = 8.0% percent of pigs

Vaccine & Administration Cost = \$1.00 per pig

Boehringer Ingelheim is committed to ongoing research for the purpose of understanding and better managing the PRRS virus. Through strategic vaccination of growing pigs, producers can significantly impact the average daily gain and mortality of their pigs.



### References

1. Johnson, C., Kliebenstein, J., Mabry, J., Neumann, E., 2004. The Impact of PRRS on the Cost of Pig Production. Allen D. Leman Swine Conference Recent Research Reports. Volume 31. pg: 11.
2. Opriessnig, T., et. al., 2005. Genomic homology of ORF 5 gene sequence between modified live vaccines and porcine reproductive and respiratory syndrome virus challenge isolates is not predictive of vaccine efficacy. Accepted for publication.
3. Roof, M.B., Vaughn, E.M., Burkhart, K.M., Faaberg, K.S., 2003. Efficacy of Modified Live Virus Porcine Reproductive and Respiratory Virus Vaccines Against Heterologous Respiratory Challenge. Proceedings 4<sup>th</sup> International Symposium on Emerging and Re-emerging Pig Diseases. Pg: 117.
4. Dee, A.D., Phillips, R.C., 1998. Using vaccination and unidirectional pig flow to control PRRSV transmission. Journal of Swine Health and Production. 1:21-21
5. Fass; Vaccination in Pigs for PRRS Control. 2003. PRRS Press. Volume 1.
6. Polson, D., et.al., 2000. Evaluating the Beneficial Performance and Financial Effects of Pig Vaccination with Ingelvac® PRRS MLV in a PRRS-Positive Multi-Site Production System. Proceedings of the 16<sup>th</sup> IPVS. Pg: 152.



Boehringer Ingelheim Vetmedica, Inc.  
2621 North Belt Highway  
St. Joseph, Missouri 64506-2002  
1-800-325-9167  
www.bi-vetmedica.com

©2005 Boehringer Ingelheim Vetmedica, Inc.  
Ingelvac is a registered trademark of Boehringer Ingelheim Vetmedica, GmbH, Ingelheim, Germany.  
Always read, understand and follow the label directions. Do not use concurrently with antibiotics.  
BI 5124511-B-1 2/05

# PRRS Vaccination for Growing Pigs



Ingelvac® PRRS MLV  
Ingelvac® PRRS ATP



Researchers continue to discover unique aspects of Porcine Reproductive and Respiratory Syndrome (PRRS) Virus infection and spread. Though the most current measures for control are targeted at sow herds, recent findings by the National Pork Board and Iowa State University indicate that more than two-thirds of the costs associated with PRRS are incurred in growing pigs.<sup>1</sup>

**It is estimated that PRRS adds between \$5.60 and \$7.60 to the cost of production per head sold.**



**Impact of PRRS Virus on Pigs in Grow/Finish**

Average Daily Gain	12% Decrease
Feed Efficiency	7.5% Decrease
Percent Mortality	166% Increase

Source: National Pork Board and Iowa State University

**Criteria for Growing Pigs Vaccination**

The chart below characterizes five potential scenarios for swine herds and PRRS status within each stage of production. By profiling each pig's origin and exposure to PRRS, a strategic decision about vaccination can be made. Could your pigs benefit from Ingelvac® PRRS vaccines?

**PRRS Profile and Vaccination Criteria**

	Breeding Herd	Nursery	Grow-Finish	Vaccinate Growing Pigs for PRRS?	Initiate a Sow Stabilization Program?
<b>1</b>	— (Not Infected)	— (Not Infected)	— (Not Infected)	No	No
<b>2</b>	— (Not Infected)	— (Not Infected)	+	Yes	No
<b>3</b>	+	— (Not Infected)	— (Not Infected)	No	No
<b>4</b>	+	— (Not Infected)	+	Yes	No
<b>5</b>	+	+	+	No	Yes

Vaccination of healthy pigs four weeks prior to field virus exposure offers significant protection against PRRS-induced respiratory disease.

Use diagnostic screening to accurately assess exposure patterns of virus and optimal vaccine placement.

Diagnostic profiling can target placement of vaccine for optimum control.

**Ingelvac PRRS Vaccines**

Ingelvac PRRS ATP and Ingelvac PRRS MLV are recommended for the vaccination of healthy, susceptible swine as an aid in the reduction of disease associated with PRRS, reproductive and respiratory.

Using an aseptic technique, administer a single 2 ml dose intramuscularly to swine 3 weeks of age or older, up to 18 weeks of age.

Results of Growing Pig Vaccination: <sup>2,3,4</sup>
Reduces viremia
Reduces shedding and transmission
Reduces clinical disease
Reduces mortality
Increases average daily gain

The full extent of vectors spreading the PRRS virus are still unknown. By utilizing biosecurity best practices and strategic vaccination in sows and growing pigs, producers can minimize the spread of the PRRS virus.



**Vaccine Efficacy**

University and large commercial trials have proven that vaccination can not only be economically beneficial, but have a significant impact on average daily gain and mortality.

**Wean to Finish PRRS Vaccination Results (13,000 head)<sup>5</sup>**

	ADG, lbs.	Mortality, %
Before Ingelvac PRRS MLV	1.3 lbs/day	15.63%
After Ingelvac PRRS MLV	1.48 lbs/day	4.49%
Difference	.18 lbs/day increase	71% reduction

Source: Fass Vaccination, PRRS Press Volume 1

**Large Nursery PRRS Vaccination Results<sup>6</sup>**

	ADG, lbs.	Mortality, %
Before Ingelvac PRRS MLV	.6 lbs/day	5%
After Ingelvac PRRS MLV	.8 lbs/day	3%
Difference	.2 lbs/day increase	40% reduction

Source: Proceeding IPVS 2000, p. 152, Polson et al.

**Controlled 14-day University Challenge Study (Three PRRS Strains)<sup>2</sup>**

	ADG, lbs.	Lung Lesions, %
Non-Vaccinates	.87 lbs/day	36.4%
Vaccinates	1.42 lbs/day	5.4%
Difference	.55 lbs/day increase	85% reduction

Source: T. Opiessnig, P. Halber, et. al.